Eli Lilly's dulaglutide gets AWARD in two more trials

Eli Lilly and Co. (NYSE:LLY) said once-weekly subcutaneous dulaglutide met the primary endpoint in two more Phase III trials to treat Type II diabetes. In 807 diabetics on metformin and glimepiride in the AWARD-2 trial, dulaglutide was non-inferior to Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) in reducing HbA1c from baseline to week 52. In 884 diabetics in the AWARD-4 trial, dulaglutide plus Lilly's Humalog insulin lispro was non-inferior to Lantus plus Humalog in reducing HbA1c from baseline to week 26.

Dulaglutide also significantly reduced HbA1c from baseline to week 52 vs. Lantus in AWARD-2, and significantly reduced HbA1c in combination with Humalog from baseline to week 26 vs. Lantus plus Humalog in AWARD-4. Both trials were designed to assess superiority of dulaglutide to Lantus if the primary endpoint of non-inferiority was met. ...